Table 2.

Pathologic and clinical outcomes

Degarelix (n = 13)Degarelix + bicalutamide (n = 14)LHRH agonist + bicalutamide (n = 12)Pa
Pathologic stage, n (%)0.449
 pT00 (0.0)2 (14.3)1 (8.3)
 pT10 (0.0)0 (0.0)0 (0.0)
 pT25 (38.5)4 (28.6)4 (33.3)
 pT38 (61.5)8 (57.1)6 (50.0)
 pT40 (0.0)0 (0.0)1 (8.3)
Extraprostatic extension, n (%)8 (61.5)8 (57.1)6 (50.0)0.843
Positive margins, n (%)5 (38.5)3 (21.4)4 (33.3)0.615
Positive nodes, n (%)3 (23.1)0 (0.0)3 (25.0)0.136
RP failure, n (%)1 (7.7)1 (7.1)1 (8.3)0.994
PSA failure (≥0.2 ng/mL) or use of adjuvant ADT or XRT, n (%)2 (15.4)4 (28.6)6 (50.0)0.169
Change in baseline Gleason scoreb0.090
 Upstaging010
 No change420
 Downstaging300
Median cancer mass, grams (range)3.44 (0.24–33.60)1.00 (0.00–12.06)1.10 (0.00–24.25)0.413
  • Abbreviation: XRT, radiotherapy.

  • aKruskall–Wallis H test.

  • bBecause of the effect of neoadjuvant hormones, pathologic Gleason score assigned for only 10 patients.